{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:02:18Z","timestamp":1780099338134,"version":"3.54.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.autrev.2026.104074","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:34:48Z","timestamp":1778196888000},"page":"104074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serious infections in antineutrophil cytoplasmic antibody-associated vasculitis: Epidemiology, risk factors, and strategies for prevention"],"prefix":"10.1016","volume":"25","author":[{"given":"Bryan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104074_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2026.104074_bb0010","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/rheumatology\/keae613","article-title":"The evolving landscape of vasculitis management: past, current and emerging","volume":"64","author":"Falk","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152609","article-title":"Defining cause of death in a contemporary cohort with ANCA-associated vasculitis (AAV): a comparison of electronic health record and death certificate data","volume":"70","author":"Katz","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104074_bb0020","doi-asserted-by":"crossref","first-page":"i171","DOI":"10.1093\/ndt\/gfv045","article-title":"Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function","volume":"30","author":"JG","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2026.104074_bb0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.autrev.2026.104074_bb0030","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis","volume":"38","author":"S\u00e1nchez \u00c1lamo","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2026.104074_bb0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12882-018-1102-3","article-title":"Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study","volume":"19","author":"Titeca-Beauport","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.autrev.2026.104074_bb0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cei\/uxae068","article-title":"An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"218","author":"Zhou","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104074_bb0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/rheumatology\/keq375","article-title":"Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission","volume":"50","author":"Tadema","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0050","article-title":"The factors predicting development of serious infections in ANCA-associated vasculitis","volume":"40","author":"Yurteri","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0055","article-title":"Lymphopenia is a risk factor for severe infections in older patients with microscopic polyangiitis: a retrospective cohort study in Japan","volume":"7","author":"Yamaguchi","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.autrev.2026.104074_bb0060","first-page":"848","article-title":"Anti-neutrophil cytoplasmic antibody patterns can predict clinical relapse in ANCA-associated vasculitis: overall population and subgroups","volume":"41","author":"Jiang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0065","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody\u2014associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0070","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10067-017-3944-7","article-title":"Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis","volume":"37","author":"La-Crette","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal Vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0090","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0095","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ekir.2025.04.030","article-title":"Combination cyclophosphamide and rituximab to minimize glucocorticoid use in antineutrophil cytoplasm antibody\u2013associated vasculitis","volume":"10","author":"Salehi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2026.104074_bb0100","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0110","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim\u2013sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0115","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3899\/jrheum.160909","article-title":"Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0120","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/14397595.2016.1226468","volume":"27","author":"Watanabe-Imai","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0125","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/rheumatology\/keaa699","article-title":"Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study","volume":"60","author":"Rathmann","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.autrev.2026.104074_bb0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-021-02452-8","article-title":"Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients","volume":"23","author":"Thomas","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104074_bb0140","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ekir.2020.12.037","article-title":"Incidence and temporal trend in risk factors of severe infections in ANCA-glomerulonephritis patients","volume":"6","author":"Jourdain","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2026.104074_bb0145","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s10067-018-4067-5","article-title":"Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis","volume":"37","author":"Yoo","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0150","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/rheumatology\/kez575","article-title":"Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group","volume":"59","author":"Lafarge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0155","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/art.43185","article-title":"Time-dependent effect of prophylactic trimethoprim-sulfamethoxazole on the incidence of serious infections in antineutrophil cytoplasmic antibody\u2013associated vasculitis: a target trial emulation study","volume":"77","author":"Kim","year":"2025","journal-title":"Arthrit Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mayocp.2019.02.024","article-title":"Vaccination of adults in general medical practice","volume":"95","author":"Hunter","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2026.104074_bb0165","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0170","first-page":"152","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in patients with ANCA vasculitis on rituximab maintenance therapy","volume":"4","author":"Aqeel","year":"2024","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0175","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/acr.25222","article-title":"Incidence of pneumocystis jiroveci pneumonia in patients with ANCA-associated vasculitis initiating therapy with rituximab or cyclophosphamide","volume":"76","author":"Nettleton","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104074_bb0180","first-page":"615","article-title":"Increased risk of pneumocystis carinii pneumonia in patients with Wegener\u2019s granulomatosis","volume":"11","author":"Jarrousse","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102986","article-title":"The COVID-19 pandemic and ANCA-associated vasculitis \u2013 reports from the EUVAS meeting and EUVAS education forum","volume":"20","author":"Kronbichler","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104074_bb0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10238-024-01351-x","article-title":"Risk factors for severe COVID-19 infection and the impact of COVID-19 infection on disease progression among patients with AAV","volume":"24","author":"Wang","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108264","article-title":"Longitudinal trends in the endemic symptomatic burden of COVID-19: insights from community-based participatory virological surveillance in the Netherlands, November 2020-April 2025","volume":"163","author":"Carstens","year":"2026","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0200","article-title":"Nationwide longitudinal analysis of COVID-19 hospitalisation burden in immunocompromised patients","volume":"15","author":"HAR","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104074_bb0205","article-title":"Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study","volume":"90","author":"Quint","year":"2025","journal-title":"J Inf Secur"},{"key":"10.1016\/j.autrev.2026.104074_bb0210","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1016\/S2665-9913(21)00316-7","article-title":"Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study","volume":"3","author":"Sattui","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.autrev.2026.104074_bb0215","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0220","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0225","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","article-title":"COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations","volume":"18","author":"Grainger","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128155","article-title":"Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: impact of immunosuppressive therapy","volume":"73","author":"Larsen","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.autrev.2026.104074_bb0235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ejcts\/ezy403","article-title":"Statistical primer: multivariable regression considerations and pitfalls\u2020","volume":"55","author":"Grant","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.autrev.2026.104074_bb0240","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2026.104074_bb0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nefroe.2021.07.005","article-title":"The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: a retrospective study","volume":"41","author":"Fonseca","year":"2021","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"10.1016\/j.autrev.2026.104074_bb0250","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keaa215","article-title":"Association between age at disease onset of anti-neutrophil cytoplasmic antibody\u2013associated vasculitis and clinical presentation and short-term outcomes","volume":"60","author":"Monti","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0255","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MD.0b013e31817c744b","article-title":"Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients","volume":"87","author":"Chen","year":"2008","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2026.104074_bb0260","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0265","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/gerona\/glv133","article-title":"Frailty in older adults: a nationally representative profile in the United States","volume":"70","author":"Bandeen-Roche","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.autrev.2026.104074_bb0270","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.autrev.2026.104074_bb0275","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","article-title":"Long-term outcomes in elderly patients with ANCA-associated vasculitis","volume":"59","author":"McGovern","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0280","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/rheumatology\/kez680","article-title":"Handgrip strength is a comorbidity marker in systemic necrotizing vasculitides and predicts the risk of fracture and serious adverse events","volume":"59","author":"Henriquez","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0285","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-021-02123-y","article-title":"Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan","volume":"21","author":"Sugiyama","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.autrev.2026.104074_bb0295","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/obr.12309","article-title":"Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects","volume":"16","author":"Veronese","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.autrev.2026.104074_bb0300","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1017\/S0007114510000152","article-title":"Body mass index and the risk of infections in institutionalised geriatric patients","volume":"103","author":"Dorner","year":"2010","journal-title":"Br J Nutr"},{"key":"10.1016\/j.autrev.2026.104074_bb0305","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/obr.12055","article-title":"Body mass index and risk of pneumonia: a systematic review and meta-analysis","volume":"14","author":"Phung","year":"2013","journal-title":"Obes Rev"},{"key":"10.1016\/j.autrev.2026.104074_bb0310","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/aje\/kwv300","article-title":"Body mass index and risk of infections among women in the Danish National Birth Cohort","volume":"183","author":"Harps\u00f8e","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.autrev.2026.104074_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105989","article-title":"Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK\/PD modelling of ANCA and gammaglobulin levels in real-world patients","volume":"121","author":"Pasquiers","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.autrev.2026.104074_bb0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cmi.2017.02.013","article-title":"Body mass index and the risk of infection - from underweight to obesity","volume":"24","author":"Dobner","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.autrev.2026.104074_bb0325","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12882-018-0933-2","article-title":"Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study","volume":"19","author":"Yang","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.autrev.2026.104074_bb0330","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2026.104074_bb0335","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/03009742.2021.2001929","article-title":"Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy","volume":"52","author":"G\u00e9rard","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0340","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4078\/jrd.2023.0031","article-title":"Recovery and long-term renal outcome of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis who are on dialysis at presentation","volume":"30","author":"Lee","year":"2023","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis","volume":"19","author":"Thery-Casari","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104074_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152189","article-title":"Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy\u2014a meta-analysis","volume":"60","author":"Pope","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104074_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2020.104039","article-title":"Lung involvement in ANCA-associated vasculitis","volume":"49","author":"Sacoto","year":"2020","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0360","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10238-025-01756-2","article-title":"A closer look to the lung involvement in ANCA-associated vasculitis: alveolar haemorrhage and interstitial lung disease","volume":"25","author":"Kaya","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0365","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2026.104074_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12931-021-01647-6","article-title":"Preexisting respiratory diseases and clinical outcomes in COVID-19: a multihospital cohort study on predominantly African American population","volume":"22","author":"Lohia","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2026.104074_bb0375","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00296-025-05812-8","article-title":"ANCA-associated vasculitis and the impact of diffuse alveolar hemorrhage in elderly patients: a retrospective cohort study","volume":"45","author":"Schaier","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104074_bb0380","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.rmed.2008.10.014","article-title":"Improving mucociliary clearance in chronic obstructive pulmonary disease","volume":"103","author":"Bhowmik","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0385","article-title":"Bacterial colonization in bronchiectasis patients","volume":"46","author":"Tertemiz","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2026.104074_bb0390","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1513\/AnnalsATS.201503-126AW","article-title":"Immune dysfunction in patients with chronic obstructive pulmonary disease","volume":"12","author":"Bhat","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.autrev.2026.104074_bb0395","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.autrev.2026.104074_bb0400","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3899\/jrheum.190065","article-title":"Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis: influence on the disease outcome","volume":"47","author":"Garcia-Vives","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0405","doi-asserted-by":"crossref","first-page":"142","DOI":"10.55563\/clinexprheumatol\/p34lkr","article-title":"Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"39","author":"Waki","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0410","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/mr\/roae024","article-title":"Risk factors for serious infections and infection-related mortality in patients with microscopic polyangiitis: multicentre REVEAL cohort study","volume":"34","author":"Manabe","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0415","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1093\/rheumatology\/kead138","article-title":"Association between hypogammaglobulinaemia and severe infections during induction therapy in ANCA-associated vasculitis: from J-CANVAS study","volume":"62","author":"Omura","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0420","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0091-6749(80)90153-0","article-title":"Long-term corticosteroid effect on lymphocyte and polymorphonuclear cell function in asthmatics","volume":"65","author":"Chiang","year":"1980","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104074_bb0425","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.4049\/jimmunol.0801829","article-title":"Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)","volume":"182","author":"Salem","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104074_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.739216","article-title":"Malnutrition contributes to low lymphocyte count in early-stage coronavirus disease-2019","volume":"8","author":"Zhang","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.autrev.2026.104074_bb0435","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-7682-5-2","article-title":"Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population","volume":"5","author":"Imtiaz","year":"2012","journal-title":"Int Arch Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0440","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/diseases9030053","article-title":"Lymphocytes as a biomarker of frailty syndrome: a scoping review","volume":"9","author":"Navarro-Mart\u00ednez","year":"2021","journal-title":"Diseases"},{"key":"10.1016\/j.autrev.2026.104074_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104074_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103130","article-title":"Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: a cohort study","volume":"142","author":"Liberatore","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104074_bb0455","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ndt\/gfad197","article-title":"Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function","volume":"39","author":"Mescia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2026.104074_bb0460","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/rheumatology\/keac716","article-title":"Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study","volume":"62","author":"Podest\u00e0","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0465","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104074_bb0470","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","article-title":"Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104074_bb0475","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2026.104074_bb0480","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.autrev.2026.104074_bb0485","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104074_bb0490","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0495","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim\u2013sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s Granulomatosis","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0500","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002424","article-title":"Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening","volume":"8","author":"Xu","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104074_bb0505","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-025-04695-y","article-title":"Trimethoprim-sulfamethoxazole and the risk of early severe infection in elderly-onset myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis","author":"Yoshida","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.autrev.2026.104074_bb0510","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1093\/rheumatology\/keab267","article-title":"The role of trimethoprim\/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis","volume":"60","author":"Monti","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0515","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/keae368","article-title":"Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab","volume":"64","author":"Mendel","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101843","article-title":"Steroid sparing in vasculitis: myth or reality?","volume":"37","author":"Hanberg","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0525","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/03009742.2023.2211387","article-title":"Efficacy and safety of low- versus high-dose glucocorticoid regimens for induction of remission of anti-neutrophil cytoplasm antibody-associated vasculitis: a systematic review and meta-analysis","volume":"52","author":"Alchi","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0530","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00296-020-04661-x","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study with a clinical phenotype approach","volume":"40","author":"Caballero-Islas","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104074_bb0535","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019173","article-title":"Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study","volume":"99","author":"Waki","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2026.104074_bb0540","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00296-020-04752-9","article-title":"Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis","volume":"41","author":"Speer","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104074_bb0545","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104074_bb0550","doi-asserted-by":"crossref","first-page":"e1199","DOI":"10.34067\/KID.0000000000000257","article-title":"Intravenous methylprednisolone in induction therapy for ANCA-associated vasculitis: how low can we go?","volume":"4","author":"Oliva-Damaso","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.autrev.2026.104074_bb0555","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.34067\/KID.0000000000000222","article-title":"Low-dose intravenous methylprednisolone in remission induction therapy for ANCA-associated vasculitis","volume":"4","author":"Floyd","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.autrev.2026.104074_bb0560","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2026.104074_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100178","article-title":"Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: a retrospective study","volume":"6","author":"Ysermans","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2026.104074_bb0570","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody\u2013associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104074_bb0575","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061339","article-title":"ExploriNg DUrable remission with rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial","volume":"12","author":"Dirikgil","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2026.104074_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100541","article-title":"Plasma exchange in patients with ANCA-associated vasculitis: a #NephJC editorial on a comPLEX question","volume":"4","author":"Krishnan","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0585","doi-asserted-by":"crossref","first-page":"i68","DOI":"10.1093\/rheumatology\/keae612","article-title":"Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances","volume":"64","author":"Odler","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104074_bb0590","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104074_bb0595","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ckj\/sfac221","article-title":"PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations","volume":"16","author":"Casal Moura","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2026.104074_bb0600","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s41927-025-00569-w","article-title":"Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"9","author":"Aldhuaina","year":"2025","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0605","article-title":"Making use of avacopan in clinical practice","volume":"19","author":"Chan","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2026.104074_bb0610","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11926-024-01149-6","article-title":"Current perspective on infections and mitigation strategies in primary systemic vasculitis","volume":"26","author":"Tumba","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2026.104074_bb0615","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104074_bb0620","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104074_bb0625","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jama.2024.13389","article-title":"CDC revises RSV vaccination recommendation for older adults in US","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104074_bb0630","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12890-022-01829-y","article-title":"Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.autrev.2026.104074_bb0635","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s10067-022-06314-9","article-title":"Predicting bacterial infection risk in patients with ANCA-associated vasculitis in Southwest China: development of a new nomogram","volume":"41","author":"Zhang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104074_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760708","article-title":"The risk of severe infections following rituximab administration in patients with autoimmune kidney diseases: Austrian ABCDE registry analysis","volume":"12","author":"Odler","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104074_bb0645","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1016\/S2665-9913(24)00193-0","article-title":"The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study","volume":"6","author":"Sattui","year":"2024","journal-title":"Lancet Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:38:20Z","timestamp":1780097900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1568997226000881"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104074","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious infections in antineutrophil cytoplasmic antibody-associated vasculitis: Epidemiology, risk factors, and strategies for prevention","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104074"}}